{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:58:38Z","timestamp":1785761918743,"version":"3.56.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.ijrobp.2015.08.033","type":"journal-article","created":{"date-parts":[[2015,8,22]],"date-time":"2015-08-22T23:30:19Z","timestamp":1440286219000},"page":"976-985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":170,"title":["Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus\u2013Associated Oropharyngeal Squamous Cell Carcinoma"],"prefix":"10.1016","volume":"93","clinical-trial-number":[{"clinical-trial-number":"nct01530997","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02281955","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Bhishamjit S.","family":"Chera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Amdur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Tepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahjat","family":"Qaqish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon L.","family":"Aumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juneko","family":"Grilley-Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Zanation","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Hackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Funkhouser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Sheets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Weissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Mendenhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.08.033_bib1","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1200\/JCO.2011.36.4596","article-title":"Human papillomavirus and rising oropharyngeal cancer incidence in the United States","volume":"29","author":"Chaturvedi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib2","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1056\/NEJMoa065497","article-title":"Case-control study of human papillomavirus and oropharyngeal cancer","volume":"356","author":"D'Souza","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib3","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJM200104123441503","article-title":"Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck","volume":"344","author":"Mork","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib4","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/1078-0432.CCR-07-1402","article-title":"Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck","volume":"14","author":"Westra","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib5","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/jnci\/djh183","article-title":"Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus","volume":"96","author":"Braakhuis","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djn011","article-title":"Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial","volume":"100","author":"Fakhry","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib7","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.2008.20.2853","article-title":"Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck","volume":"27","author":"Lassen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib9","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","article-title":"Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis","volume":"26","author":"Machtay","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib10","unstructured":"Radiation therapy oncology group. Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-Associated oropharynx cancer. Available at: www.rtog.org\/ClinicalTrials\/ProtocolTable\/StudyDetails.aspx?study=1016. Accessed July 16,\u00a02014."},{"key":"10.1016\/j.ijrobp.2015.08.033_bib11","unstructured":"Radiation therapy oncology group. randomized phase II trial of transoral endoscopic head and neck surgery followed by risk-based IMRT\u00a0and\u00a0weekly cisplatin versus IMRT and weekly cisplatin for HPV\u00a0negative\u00a0oropharynx cancer. Available at: www.rtog.org\/ClinicalTrials\/ProtocolTable\/StudyDetails.aspx?study=1221. Accessed August 19,\u00a02014."},{"key":"10.1016\/j.ijrobp.2015.08.033_bib12","unstructured":"ECOG-ACRIN. Transoral surgery followed by low-dose or standard-dose radiation therapy with or without chemotherapy in treating patients with HPV positive stage III-IVA oropharyngeal cancer. Available at: http:\/\/ecog-acrin.org\/clinical-trials\/e3311-educational-materials. Accessed October 1,\u00a02014."},{"key":"10.1016\/j.ijrobp.2015.08.033_bib13","doi-asserted-by":"crossref","unstructured":"Cmelak A, Li S, Marur S, et\u00a0al. E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC). ASCO Meeting Abstracts, 2014;32(18 Suppl):LBA6006.","DOI":"10.1200\/jco.2014.32.18_suppl.lba6006"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archotol.1991.01870180037007","article-title":"Standardizing neck dissection terminology. Official report of the Academy's Committee for Head and Neck Surgery and Oncology","volume":"117","author":"Robbins","year":"1991","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib17","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju127","article-title":"Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials","volume":"106","author":"Chera","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/JCO.1999.17.3.1008","article-title":"Quality of life in\u00a0head and neck cancer patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35","volume":"17","author":"Bjordal","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/000348940811701210","article-title":"Validity and reliability of the Eating Assessment Tool (EAT-10)","volume":"117","author":"Belafsky","year":"2008","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/archotol.128.1.44","article-title":"Development and validation of the neck dissection impairment index: A quality of life measure","volume":"128","author":"Taylor","year":"2002","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/BF00417897","article-title":"A penetration-aspiration scale","volume":"11","author":"Rosenbek","year":"1996","journal-title":"Dysphagia"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib23","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1097\/00005537-199911000-00010","article-title":"Management implications of evaluating the N2 and N3 neck after organ preservation therapy","volume":"109","author":"Strasser","year":"1999","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib24","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(13)70011-1","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial","volume":"14","author":"Haddad","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib26","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib27","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1002\/cncr.25189","article-title":"Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer","volume":"116","author":"Newlin","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/hed.21224","article-title":"Comprehensive IMRT plus weekly cisplatin for advanced head and neck cancer: The University of Wisconsin experience","volume":"32","author":"Traynor","year":"2010","journal-title":"Head Neck"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.radonc.2006.03.010","article-title":"A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas","volume":"79","author":"Medina","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib30","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/annonc\/mdq219","article-title":"Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: A phase II randomized trial","volume":"21","author":"Sharma","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib31","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Available at: www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed December 15,\u00a02014."},{"key":"10.1016\/j.ijrobp.2015.08.033_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0360-3016(93)90167-T","article-title":"Evaluation of the dose for postoperative radiation therapy of head and neck cancer: First report of a prospective randomized trial","volume":"26","author":"Peters","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib33","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/cncr.23279","article-title":"Lymph node-positive head and neck cancer treated with definitive radiotherapy: Can treatment response determine the extent of neck dissection?","volume":"112","author":"Yeung","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib34","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data\u00a0from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijrobp.2013.12.027","article-title":"Final results of local-regional control and late toxicity of RTOG 9003: A randomized trial of altered fractionation radiation for locally advanced head and neck cancer","volume":"89","author":"Beitler","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000355194","article-title":"Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma","volume":"85","author":"Ley","year":"2013","journal-title":"Oncology"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib38","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ijrobp.2010.07.008","article-title":"Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer","volume":"81","author":"Koutcher","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ijrobp.2009.02.015","article-title":"The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas","volume":"74","author":"Kong","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib40","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.ejca.2010.04.016","article-title":"Relationships between epidermal growth factor receptor expression and human papillomavirus status as markers of prognosis in oropharyngeal cancer","volume":"46","author":"Hong","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib41","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/hed.21669","article-title":"Transoral laser microsurgery as primary treatment for advanced-stage oropharyngeal cancer: A United States multicenter study","volume":"33","author":"Haughey","year":"2011","journal-title":"Head Neck"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib42","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/cncr.20069","article-title":"Is concurrent chemoradiation the treatment of choice for all patients with stage III or IV head and neck carcinoma?","volume":"100","author":"Garden","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2012.44.0164","article-title":"Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis","volume":"31","author":"O'Sullivan","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.08.033_bib44","unstructured":"NRG Oncology. NRG-HN002: A randomized phase II trial for patients\u00a0with p16 positive, non-smoking associated, locoregionally advanced oropharyngeal cancer, NCT02254278. Available at: https:\/\/www.nrgoncology.org\/Protocols\/NRG-HN002. Accessed January 1,\u00a02015."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615031909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615031909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T03:48:55Z","timestamp":1748576935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615031909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0360301615031909"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.08.033","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 2 Trial of De-intensified Chemoradiation Therapy for Favorable-Risk Human Papillomavirus\u2013Associated Oropharyngeal Squamous Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.08.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}